文献速递肿瘤 PET/CT

18F-PSMA-1007 PET/CT对前列腺癌淋巴结分期的诊断准确性

Diagnostic Accuracy of 18F-PSMA-1007 PET/CT Imaging for Lymph Node Staging of Prostate Carcinoma in Primary and Biochemical Recurrence.
PubMed 文献 · J Nucl Med · 2020-08-17

该研究回顾性分析了96例前列腺癌患者,在根治性前列腺切除加淋巴结清扫或挽救性淋巴结清扫前行18F-PSMA-1007 PET/CT,以组织病理学为参考标准。结果显示,对大于3 mm的阳性淋巴结,病灶灵敏度81.7%、特异度99.6%;患者水平灵敏度85.9%、特异度99.5%。18F-PSMA-1007 PET/CT能可靠检出恶性淋巴结,特异度超过99%。

要点

  • 对大于3 mm的淋巴结,病灶灵敏度81.7%、特异度99.6%。
  • 患者水平分析灵敏度85.9%、特异度99.5%。
  • 18F-PSMA-1007 PET/CT对淋巴结转移特异度超过99%。

核心结论

  • 18F-PSMA-1007 PET/CT能可靠检出前列腺癌恶性淋巴结,对淋巴结转移的特异度超过99%。

研究设计与样本

  • 回顾性分析96例前列腺癌患者,行18F-PSMA-1007 PET/CT后接受根治性前列腺切除加淋巴结清扫或挽救性淋巴结清扫。
  • 90.6%的患者为初治前分期,9.4%的患者因生化复发接受显像。
  • 共清扫1746枚淋巴结,行基于病灶和基于患者的分析,比较所有阳性病灶与病理大于3 mm的病灶。

主要发现

  • 34.4%的患者显像显示阳性淋巴结。
  • 对大于3 mm的阳性淋巴结,病灶灵敏度81.7%、特异度99.6%、阳性预测值92.4%、阴性预测值98.9%。
  • 对所有恶性淋巴结(不论大小),病灶灵敏度71.2%、特异度99.5%、阳性预测值91.3%、阴性预测值97.9%。
  • 患者水平分析对大于3 mm的淋巴结灵敏度85.9%、特异度99.5%。

临床怎么用

  • 18F-PSMA-1007 PET/CT可用于前列腺癌初治前淋巴结分期或生化复发灶定位,其高特异度有助于确认淋巴结转移。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Prostate-specific membrane antigen (PSMA)-ligand PET/CT is performed on patients with prostate cancer to stage the disease initially or to identify sites of recurrence after definitive therapy. On the basis of clinical results, 18F-PSMA-1007 is a promising PSMA PET tracer, but detailed histologic confirmation has been lacking. Methods: Ninety-six patients with prostate cancer underwent 18F-PSMA-1007 PET/CT followed by either radical prostatectomy with lymphadenectomy or salvage lymphadenectomy. The histologic findings of PSMA PET-positive nodes were analyzed retrospectively. A lesion-based and patient-based analysis was performed comparing all positive lesions and only lesions larger than 3 mm on histopathology. Results: Of the patients, 90.6% received 18F-PSMA-1007 PET/CT for staging before the primary treatment, whereas 9.4% underwent imaging for biochemical recurrence. In 34.4% of the cohort, positive lymph nodes were present on imaging. In total, 1,746 lymph nodes were dissected in 96 patients. 18F-PSMA-1007 PET had a lesion-based sensitivity of 81.7%, a specificity of 99.6%, a positive predictive value of 92.4%, and a negative predictive value of 98.9% for detecting positive lymph nodes larger than 3 mm. In the analysis of all malignant nodes regardless of size, the overall sensitivity, specificity, positive predictive value, and negative predictive value on lesion-based analysis were 71.2%, 99.5%, 91.3%, and 97.9%, respectively. The patient-based analysis showed a sensitivity of 85.9% and a specificity of 99.5% for lymph nodes larger than 3 mm. Conclusion:18F-PSMA-1007 PET/CT reliably detects malignant lymph nodes and has an exceptional specificity of more than 99% for nodal metastases.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Sprute K, Kramer V, Koerber SA, et al. Diagnostic Accuracy of 18F-PSMA-1007 PET/CT Imaging for Lymph Node Staging of Prostate Carcinoma in Primary and Biochemical Recurrence. J Nucl Med. 2020. PMID: 32817141. doi:10.2967/jnumed.120.246363

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。